SIRNAOMICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.55 HKD | +3.97% |
|
+12.35% | -81.70% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8369
USD
Average target price
9.231
USD
Spread / Average Target
+1,003.06%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -81.70% | 69.87M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 2257 Stock
- News Sirnaomics Ltd.
- Mobvista Swings to Profit in 2022
